2000 contracts Sept 16 - 18 and you choose to point out the lousy 75 on Oct 18. the pointere is that this may yetbe another short manipulation to hravest sept call premiums. but time willl tell.
yes, believe it or not there was a time long ago i was a very good speller.
i cannot type worth a dam, too much reliance on spell check to keep the skill up.
yes JT, it has been quite a while since we longs have seen such a day as today. ( yes i still have 10,500 shares)
better than being down $1.37 that is for sure.
yah like PFE as rweal bright in walking away from rindo. that is what worries you, too funny
we will soon be at 99 % IO and the rest will be play out as planed with time.
yes we all know and agree with you on this point. but that is old news.
if you think he was smart enough to fix the PII results, please tell us how he did it, if not please stop beating the same drum, it servces no purpose. CEO is slime - check. STS PII results seem interesting - check.
three months from now CEO will still be slime - check. will PII OS data be good, that is the unknown.
if you want to accumulate a shred of crdibility, start trashing the PII study with some back up of your position.
with a maipulated stock. look for close below $16 by option expiry ( sept 19th)
IO do not bother with options.
PRO shorts typicallay run up the price - write call options and then tank the price to bank the call premium. not hapenning today.
Shorts should have stepped in this mroning to stem the rise, but they have not done so.
if they do not tank it into the close, this run may just continue rthe rest of the week.
if we see an entire week of 10% gains like last year then we have turned thew corner. if not it will give ths gain back in little time. good news will be that SI will have to go up yet again the keep the price down.
lets see 30% SI with 99% IO in the net two months.
Thank you for your inquiry. CytRx is aware of this paper, but they are not looking at SPARC in their Phase 2b or Phase 3 sarcoma studies because there is no conclusive data about its role. There are other publications that show that high expressers of SPARC fare better in certain cancers, which is in contrast to this paper which shows high expressers fare worse. Further, the current thinking out of the albumin workshop at the Controlled Release Society meeting earlier this summer is that SPARC is probably not the right marker to be looking at in regards to albumin-related therapies.
what stops them from taking cldx out at $40? It will go at whatever the IO want, they controll things not management.
AM can say no all he wants, he does not matter anymore.
AM is a dreamer when he says he plas to go it alone. 97 IO says CLDX is ripe for the kill.
question is is AM smart enough to maximize proceeds for shareholders, if so how will he go about it.
start by raising the poison pill $ trigger for one thing. Needs muliptle PTs going forward.
97% IO and 20% SI is simply crazy.
Strong React and METRIC results and its lights out. He needs to keep 027 as that is where the big $$ are. But with 97% IO he cann't even spin it out into a new corp to maximize valuation although its worth a shot.. His best hope is a PT where he keeps 50% of the value.
at $3 its worth the gamble. IF OS are in aldox favour even if not statistically significant, all the better. GBM is a real long shot, late 2015 to know anything, but if it hits, its a grand slam. Long odds , very big pay off.
buy more at this level. they have the cash to get to results of current studies. cardio tox and PFS likley good ebough to get ALDOX approval. the cardio tox benefit is real that is not subject to skewing.
shiorts need to add 1 million shares per month to their position to keep the price down. If Rindo results are good in Nov, they will need to double that number or cover. They will eventually need t cover. Their only out is poor results.